2017 Blood Lead Surveillance Report

Minnesota Department of Health
Lead and Healthy Homes Program
PO Box 64975
St. Paul, MN 55164-0975
(651) 201-4620
health.asbestos-lead@state.mn.us
www.health.state.mn.us

As requested by Minnesota Statutes 3.197: This report cost approximately $5,000 to prepare, including staff time, printing and mailing expenses. Funding for the creation of this report was provided by the Centers for Disease Control and Prevention (CDC) Childhood Lead Poisoning Prevention Grant CDC-RFA-EH14-1408PPHF14

Upon request, this material will be made available in an alternative format such as large print, Braille or audio recording. Printed on recycled paper.
Contents

Acronyms and Abbreviations .............................................................................................................. 5
Executive Summary ............................................................................................................................. 6
Lead Exposure ........................................................................................................................................ 7
Elevated Blood Lead Levels .............................................................................................................. 8
State Blood Lead Guidelines ............................................................................................................ 9
  Childhood Blood Lead Case Management Guidelines .................................................................. 9
  Blood Lead Screening Guidelines for Pregnant Women ............................................................... 9
  Childhood Blood Lead Screening Guidelines ............................................................................ 10
  Childhood Blood Lead Clinical Treatment Guidelines ............................................................. 10
Data Collection .................................................................................................................................. 10
  Lead Testing ................................................................................................................................. 10
  LeadCare® Recall ........................................................................................................................ 11
  The MN Blood Lead Information System (BLIS) ....................................................................... 12
Statewide Surveillance Data ............................................................................................................. 13
Childhood Blood Lead Screening .................................................................................................... 13
Elevated Blood Lead Levels in Children .......................................................................................... 13
  Geographic Variability in Elevated Blood Lead Levels ............................................................ 14
  Demographics ............................................................................................................................. 15
  Special Populations: Medicaid Enrolled Children ................................................................... 15
  Special Populations: Refugee Children ....................................................................................... 16
Case Management ............................................................................................................................ 16
  Follow-up Testing ........................................................................................................................ 17
  Environmental Risk Assessments ............................................................................................... 18
Adults ................................................................................................................................................ 20
Evaluation of BLIS ............................................................................................................................ 22
  Completeness ................................................................................................................................. 22
  Timing ............................................................................................................................................. 23
Other Resources Available from LHHP ............................................................................................ 24
  M-CLEAN ..................................................................................................................................... 24
  Swab Team Services Grants ......................................................................................................... 24
  Healthy Homes Information .......................................................................................................... 24
Further Lead Information ..................................................................................................... 25
## Acronyms and Abbreviations

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABLES</td>
<td>Adult Blood Lead Epidemiology and Surveillance Program</td>
</tr>
<tr>
<td>BLIS</td>
<td>Blood Lead Information System</td>
</tr>
<tr>
<td>BLL</td>
<td>Blood Lead Level (µg/dL)</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>DHS</td>
<td>Minnesota Department of Human Services</td>
</tr>
<tr>
<td>EBLL</td>
<td>Elevated Blood Lead Level</td>
</tr>
<tr>
<td>EPSDT</td>
<td>Medicaid’s Early and Periodic Screening, Diagnosis, and Treatment Program</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>IQ</td>
<td>Intelligence Quotient</td>
</tr>
<tr>
<td>LHHP</td>
<td>MDH Lead and Healthy Homes Program</td>
</tr>
<tr>
<td>MA</td>
<td>Minnesota Medical Assistance, Minnesota’s Medicaid program</td>
</tr>
<tr>
<td>M-CLEAN</td>
<td>Minnesota Collaborative Lead Education and Assessment Network</td>
</tr>
<tr>
<td>MDH</td>
<td>Minnesota Department of Health</td>
</tr>
<tr>
<td>MEDSS</td>
<td>Minnesota Electronic Disease Surveillance System</td>
</tr>
<tr>
<td>MN</td>
<td>Minnesota</td>
</tr>
<tr>
<td>MNCare</td>
<td>MinnesotaCare, a public health care program for Minnesotans with low incomes</td>
</tr>
<tr>
<td>MNOSHA</td>
<td>Minnesota Occupational Safety and Health Administration</td>
</tr>
<tr>
<td>NIOSH</td>
<td>National Institute for Occupational Safety and Health</td>
</tr>
<tr>
<td>PPB</td>
<td>Parts Per Billion</td>
</tr>
<tr>
<td>U.S.</td>
<td>United States</td>
</tr>
<tr>
<td>µg/dL</td>
<td>Micrograms of lead per deciliter of whole blood</td>
</tr>
</tbody>
</table>
Executive Summary

This 2017 Blood Lead Surveillance Report describes the activities of the Minnesota Department of Health (MDH) Lead and Healthy Homes Program (LHHP) and the data analysis from the MDH Blood Lead Information System (BLIS) for the 2017 calendar year. The report contains a description of the trends in lead testing and elevated blood lead levels in Minnesota.

In 2017, over 92,500 Minnesota children received at least one blood lead test. Of these, 757 (under 1%) were found to have an elevated blood lead level. This number has been decreasing over the past decades. However, there are some populations and areas in Minnesota that have a much higher proportion with elevated blood lead levels than others.

Childhood blood lead screening has improved in Minnesota since 2000. Approximately 81% of children born in 2014 were tested at least once prior to their third birthday in 2017, compared to 42% of those born in 2000. However, further increases in the percent tested have not been seen since the 80% point was first reached by children born in 2008. In addition, only about one-third of children receive blood lead tests at both one and two years of age.

Once a child is detected as potentially having an elevated blood lead level (5+ µg/dL) through a screening test, a diagnostic follow-up test is recommended. In 2017, 72% of children with an elevated screening test received a follow-up test within the recommended time period. Local public health agencies provide case management services, ranging from educational mailings to home visits, to all children with elevated blood lead levels. If a child’s blood lead level is very elevated, over 15 µg/dL, an environmental risk assessment of the child’s residence by a licensed risk assessor is mandated. In 2017, there were 82 children with confirmed blood lead levels over 15 µg/dL. Risk assessments identified lead-based paint and lead contaminated dust hazards in the homes of most of these children.

In addition to childhood lead exposure, adults can also be exposed to lead. Most adult lead exposures are occupational. In 2017, 983 Minnesota adults were found to have elevated blood lead levels. Common industries where workers were exposed in 2017 included secondary smelting, sporting and athletic goods manufacturing (includes fishing sinker manufacturing), and small arms ammunition manufacturing.

Lead exposure surveillance through the Minnesota Blood Lead Information System enables the identification and response to lead exposures as well as monitoring of trends and patterns in the population. MDH also contributes to regional and national efforts to formulate strategies for identifying and preventing exposure to lead. MDH currently receives funding from state and federal sources, including funds from the Centers for Disease Control and Prevention (CDC) to support these activities. Ongoing investment is necessary to maintain data collection, entry, analysis, and quality assurance.
Lead Exposure

Although the toxicity of lead has been known for thousands of years, lead remains one of the most common environmental health threats to children. There are many sources of lead exposure, such as soil contaminated from years of leaded gasoline use, lead dust accidentally brought home from parents’ workplaces and hobby areas, lead in plumbing, and some imported products and traditional remedies. However, deteriorated lead paint in homes remains the main source of lead exposure for U.S. children today. As lead paint deteriorates, it creates fine dust that is identical in appearance to ordinary house dust. Although lead paint was banned for residential use in 1978, many older homes still contain lead paint. It is estimated that nearly one million homes throughout Minnesota still have lead paint.

Elevated levels of blood lead occurring during the first years of life may not produce symptoms until the children enter school and display learning difficulties, reduction in IQ, or behavior problems.

Children less than six years old are most vulnerable to lead’s toxicity due to their growing bodies, nutritional needs, mouthing behavior, and time spent on the floor. Pregnant women and the developing fetus are also at greater risk because lead easily passes through the placenta to the fetus. The changing nutritional needs of the mother also cause release of lead stored in bone. Certain populations are at increased risk of lead exposure. For example, children enrolled in medical assistance programs are more likely to live in poverty and therefore live in old, poorly maintained housing, which is more likely to contain lead paint hazards. 1,2 Refugees arriving in Minnesota have also been found to be at increased risk for elevated blood lead levels, potentially due to lead exposure prior to their arrival. 3

---

Elevated Blood Lead Levels

The Centers for Disease Control and Prevention’s current reference level for an elevated blood lead level is 5 micrograms of lead per deciliter whole blood (µg/dL) (Figure 1). This value is based on the 97.5th percentile of the blood lead distribution among U.S. children and is expected to be lowered as average blood lead levels continue to decline. Confirmed blood lead test results above the 5 µg/dL reference value are expected to trigger a public health response. CDC also acknowledges that there is no safe level of exposure to lead, and the effects of lead exposure appear to be irreversible. Therefore, primary prevention, or preventing lead exposure before it can start, is crucial.

Under Minnesota Statutes 144.9501, Subd. 9, the definition of an elevated blood lead level (EBLL) in Minnesota is a diagnostic blood lead test of at least 5 µg/dL, consistent with Minnesota case management guidelines and CDC recommendations.

Minnesota Statutes 144.9504 mandates environmental interventions for venous blood lead levels of 15 µg/dL or greater in children less than six years old. For levels of 5 µg/dL or greater, local public health nurses work with families to bring down elevated lead levels. For most children and adults exposed to lead, identification and elimination of the source of lead is the primary intervention.

Figure 1. Historic CDC Recommendations of Elevated Blood Lead Level Thresholds for Public Health Response
State Blood Lead Guidelines

MDH has a set of four guidelines available for lead: Childhood Blood Lead Case Management, Blood Lead Screening for Pregnant Women, Childhood Blood Lead Screening, and Childhood Blood Lead Clinical Treatment, which may be found at the MDH Web site at www.health.state.mn.us/lead. These guidelines are intended to establish standardized screening practices and minimum levels of care for providing services to children. However, local health departments that have greater resources available may wish to take a more rigorous approach to case management.

Childhood Blood Lead Case Management Guidelines

REVISED DECEMBER, 2017

The Case Management Guidelines work in concert with the MDH Blood Lead Screening Guidelines for Minnesota to identify and manage lead exposure in children. A qualified case manager should oversee the treatment and recovery of each child, and ensure that steps are taken to prevent further exposure of the child to potential sources of lead. Appropriate steps are presented for both capillary and venous test results, as well as information on the case manager’s role, environmental risk assessments, home visits, sources of lead, referrals, and resources. The Childhood Blood Lead Case Management Guidelines for Minnesota was first released in 2001. The 2017 Revision was updated based on national recommendations, changes to the elevated blood lead level definition (≥5 μg/dL), and input from a multi-disciplinary workgroup. In addition to the reference manual, there is also an accompanying Childhood Blood Lead Case Management Guidelines Summary, a two-page summary document for a quick verification of intervention recommendations for each blood lead level.

Blood Lead Screening Guidelines for Pregnant Women

REVISED AUGUST, 2015

The Blood Lead Screening Guidelines for Pregnant Women in Minnesota are designed to assist health care providers in screening pregnant women for elevated blood lead levels. Not every woman is at risk for lead exposure, so a risk screening questionnaire should be used to decide whether testing is recommended. Examples of risk factors for lead exposure include occupational exposure of the mother or another household contact, remodeling a home containing lead paint, using non-commercial home remedies that contain lead, and pica behavior. Identifying and preventing elevated blood lead levels in pregnant women also serves to protect the developing fetus. The 2015 revision reflects the current definition of an elevated blood lead level (5+ μg/dL), provides additional details on sources of lead, and includes resources specific to Minnesota.
Childhood Blood Lead Screening Guidelines

REVISED MARCH, 2011

The MDH Childhood Blood Lead Screening Guidelines direct physicians to order blood lead tests for:

1. Children residing in specific geographic areas that have high rates of elevated blood lead
2. Children matching specific groups that have high rates of elevated blood lead

Universal testing is recommended for children residing in Minneapolis and St. Paul and those recently arriving from other major metropolitan areas or other countries. Testing is also recommended for children receiving Medicaid. The tests are typically performed when the child is one and two years old, but may be done at any time if the parent is concerned or if a high-risk activity (e.g. remodeling a home built before 1950) has recently occurred. It is recommended that physicians use the Minnesota blood lead screening risk questionnaire to help determine if a child is at high risk for lead exposure (available at: http://www.health.state.mn.us/divs/eh/lead/reports/screening/blsg4mn.pdf).

Childhood Blood Lead Clinical Treatment Guidelines

REVISED MARCH, 2011

The Childhood Blood Lead Clinical Treatment Guidelines are designed to assist health care providers in following up with patients with elevated blood lead levels. The clinical treatment guidelines recommend engaging families through education at blood lead levels of 5–10 µg/dL. Additional diagnostic tests and interventions, such as radiographs, additional bloodwork, and chelation therapy, are recommended for higher blood lead levels.

Data Collection

Lead Testing

Since not all Minnesota children have a high risk for lead exposure, targeted testing based on established risk factors is recommended for most areas of the state. Children should be evaluated using a screening questionnaire to determine whether they have risk factors for lead exposure; the goal is to test all children who are at risk for exposure to lead. Because lead testing is neither universal nor randomly sampled, the data in this report are not generalizable to the population of children living in Minnesota. However, a large proportion of Minnesota children are tested at least once prior to their third birthday. Of children born in 2014, 81% were tested at least once by their third birthday in 2017.

The blood specimens used in blood lead testing are drawn from either capillaries or veins. Tests on capillary blood are considered “screening” tests. They are drawn from a finger stick, allowing them to be performed in a wide range of settings. However, Minnesota lead testing data
suggest that about 60% of elevated capillary screening tests may be false positives. Therefore, a follow-up diagnostic test is needed to confirm an elevated capillary test. Venous specimens are drawn from a vein and are considered “diagnostic” because they are less prone to false positives than capillary tests. However, they can be more difficult to obtain. Venous tests are required to initiate an environmental investigation of an elevated lead result.

**LeadCare® Recall**

LeadCare® Testing Systems are a family of blood lead analyzers commonly used for point-of-care testing. LeadCare® machines had been approved for testing on capillary and venous blood specimens, however, a safety communication and Class 1 recall were issued in May 2017 by the U.S Food and Drug Administration (FDA) for all LeadCare® machines because they were giving falsely low test results when processing tests on venous samples. CDC recommended that children less than 6 years of age and pregnant women who had venous samples analyzed on LeadCare® machines have their blood retested for lead. This recall did not affect tests on capillary samples analyzed on LeadCare® machines, and LeadCare® machines are still frequently used to perform blood lead tests on capillary samples.

In response to the recall, MDH identified laboratories with LeadCare® devices. These laboratories, along with local public health agencies, were sent lists of patients who met retesting criteria. They were encouraged to ensure that retesting was completed for individuals according to CDC’s criteria as well as for refugees 6–17 years of age. MDH identified 26,494 persons who received a pre-recall test during 2007–2017 meeting retesting criteria, including 1,529 persons who had a prior EBLL (Figure 2). As of July 5, 2018, MDH has received retests for 5,207 (20%) of those identified to be retested. This number includes 4,282 of 18,155 children (24%), 844 of 7,113 adult women (12%), and 168 of 1,632 refugees (10%). Among the 1,529 persons who had a previous EBLL, 519 (34%) have been retested.

**Figure 2. Number of Persons Retested and Identified for Retesting Due to LeadCare® Recall, by Category.**

![Figure 2](image-url)

---

To date, individuals who had a pre-recall test in 2016 or 2017 have been more likely to receive a retest than those whose pre-recall test occurred prior to 2016. Of those with a pre-recall test during 2016–2017, 26% have received a retest, compared to 10% of individuals with a pre-recall test during 2012–2015. Only 2% of the individuals with a pre-recall test during 2007–2011 have received a retest.

Of individuals who have been retested, 80 persons (2%) had an elevated blood lead result following the recall. Of those, 39 (49%) were confirmed with a subsequent elevated test and 34 (43%) were confirmed to be non-cases with a subsequent result under 5 μg/dL. Seven individuals (9%) have not yet received confirmatory testing.

**The MN Blood Lead Information System (BLIS)**

MDH maintains a blood lead information system (BLIS) for tracking and monitoring trends in blood lead levels in adults and children in Minnesota. Laboratories submit results to the LHHP, as mandated by Minnesota Statutes 144.9502. The data are used to help identify populations at risk for elevated blood lead levels (EBLLs), to help ensure that screening services are provided to groups identified as having the highest risk of lead exposure, and to ensure that environmental and medical follow-up are provided to children with EBLLs. Data are also used to plan, develop, and implement primary prevention programs.
Statewide Surveillance Data

Statewide data are available starting from 1995. Data for years 2000–2016 are shown for comparison to the 2017 data. The number of children tested for lead in Minnesota increased steadily from 2000 through 2008, decreased slightly during 2009–2015, and increased again in 2016 and 2017. In 2017, 92,534 children aged less than 6 years were tested (Figure 3).

Blood lead screening for older children (aged 6 to 15 years) and adults is much less common than for young children. Older children are not recommended to be routinely screened and tend to only receive blood lead tests if a provider has reason to suspect the child may be lead-exposed, such as recent immigration to the U.S., a lead-related hobby, or the child is symptomatic. In 2017, 2,870 children aged 6 to 15 years received a blood lead test.

Adults are primarily blood lead tested if they are pregnant or at risk for occupational lead exposure. In many cases, this testing is part of routine medical monitoring programs implemented by their employers. In 2017, 9,361 adults (aged 16+) were blood lead tested.

Figure 3. Number of Persons Blood Lead Tested by Year and Age Group, Minnesota, 2000–2017.

Childhood Blood Lead Screening

While Minnesota’s blood lead screening guidelines do not recommend universal testing for children in all areas of the state, the percentage of children tested has been increasing over time. To examine testing rates in children, a birth cohort approach can be useful. This approach looks at all children born in a given year and measures how many of these children receive blood lead screening at specific benchmarks. These benchmarks include the percent of children who receive at least one test by three years of age, the percent who receive a blood lead test
around one year of age, the percent tested around two years of age, and the percent tested at both one year and two years of age.

The most recent birth cohort to have been observed for a full three years is children born in 2014. Among the 69,916 children born in 2014, 56,332 children (81%) statewide were tested at least once by age three years. Among children in Minneapolis and St. Paul, where universal screening is recommended, 86% were tested at least once. Elsewhere in the state, 80% were tested at least once. (Figure 4)

**Figure 4. Number and Percent of Children Tested at least Once by Age 3 Years by Birth Cohort**

Within the 2014 birth cohort, while 81% of children were tested at least once by age three, 69% were tested around one year of age (9 to 18 months), 45% were tested around two years of age (18 to 36 months), and only 34% were tested at both one and two years of age (Figure 5). This indicates that many providers are testing children at one year but not two years of age.

Two year old children are more mobile and interact with their environments differently than one year old children. This can change the risk for lead exposure between these ages, even if the child’s house or other risk factors do not change.

This is supported by MDH surveillance data; about 0.5% of children with non-elevated (<5 µg/dL) blood lead levels measured at one year of age who were tested at two years of age have a confirmed elevated blood lead level at the time of the second test. This indicates that the practice of not testing children at two years of age may lead to lead-exposed children going undetected.

Blood lead screening statistics are available at the county scale through the MDH Data Access Portal’s Childhood Lead Exposure page (https://apps.health.state.mn.us/mndata/lead).
Elevated Blood Lead Levels in Children

Trends in the prevalence of lead exposure in Minnesota children can be understood through examining trends in the number of children with detected EBLLs per year (Figure 6). The number of EBLL cases has continued to decrease in recent years. However, in 2017, there were still 757 Minnesota children who had confirmed blood lead levels of at least 5 μg/dL, 82 of whom had confirmed blood lead levels of at least 15 μg/dL. The highest confirmed blood lead level identified in a child from Minnesota in 2017 was 76 μg/dL.

Figure 6. Number of Children with Confirmed and Unconfirmed Elevated Blood Lead Levels (5+ μg/dL and 15+ μg/dL) by Year of Test, 2001–2017

A confirmed elevated blood lead level is defined here as any elevated venous blood lead test result or any elevated capillary blood lead test result followed-up by a second elevated capillary test within 12 weeks. An unconfirmed elevated blood lead level is an elevated capillary blood lead test without a follow-up test. Elevated capillary tests that receive a non-elevated venous follow-up test within 12 weeks are excluded since these are likely to be false positive tests. The true number of children with elevated blood lead levels is likely somewhere between the total (confirmed and unconfirmed) count and the confirmed count. In 2017 for levels 5 μg/dL or greater, this would be somewhere between 757 and 1,049. In 2017, 92,534 children were blood lead tested and 757 (0.8%) had a confirmed EBLL of 5 μg/dL or greater while 82 (0.1%) had a confirmed EBLL of 15 μg/dL or greater (Figure 7).

---

Geographic Variability in Elevated Blood Lead Levels

County-level data regarding blood lead testing and the distribution of EBLLs among Minnesota children are available on the MDH Data Access Portal’s Childhood Lead Exposure page (https://apps.health.state.mn.us/mndata/lead). (Figure 8).

While the percent of children with elevated blood lead levels among tested children continues to decline statewide, there remain geographic areas where a much higher percent of children are found to have EBLLs. The majority of high percent-EBLL census tracts are found in the cities of Minneapolis and St. Paul, but can also be found in rural areas of the state. Tracts with higher percent-EBLL tend to have more houses built prior to 1950, a larger proportion of the population living in poverty, and a larger proportion of the population being persons of color than lower percent-EBLL tracts.
Demographics

The demographic indicators gender, race, and ethnicity are collected by MDH with blood lead test results. While reporting gender and race with the results of a blood lead test is required under Minnesota Statutes 144.9502, MDH accepts records where these are reported as “Unknown.” Gender data tends to be mostly complete; race and ethnicity are often reported as “Unknown.” This creates a problem for monitoring racial disparities in lead testing and lead exposure.

In 2017, blood lead test results for children aged less than six years were reported for 46,987 males, 44,582 females, and 49 persons whom gender was not reported. The percentage of confirmed EBLLs was not significantly different between males and females (Table 1).

Table 1. Summary of the Reported Demographic Characteristics of Children Aged < 6 Years Blood Lead Tested in 2017 and EBLL Cases (Confirmed ≥5 µg/dL)

<table>
<thead>
<tr>
<th>Demographic</th>
<th>Tested, n (%)</th>
<th>EBLL Cases, n</th>
<th>Percent EBLL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>44,582 (49%)</td>
<td>418</td>
<td>0.9%</td>
</tr>
<tr>
<td>Male</td>
<td>46,987 (51%)</td>
<td>339</td>
<td>0.7%</td>
</tr>
<tr>
<td>Unknown</td>
<td>49 (0%)</td>
<td>0</td>
<td>0%</td>
</tr>
</tbody>
</table>

Racial and ethnic disparities in the prevalence of lead poisoning have been shown in national data. A recent summary of 2007–2010 data from the National Health and Nutrition Examination Survey for U.S. children aged 1–5 years showed the geometric mean blood lead level of White, non-Hispanic children was 1.3 µg/dL while that of Black, non-Hispanic children was significantly higher at 1.8 µg/dL. The geometric mean blood lead level of Mexican American children was also 1.3 µg/dL. Individual race and ethnicity data reported with blood lead tests is too incomplete to provide reliable estimates of racial and ethnic disparities in Minnesota, however, the LHHP is working to improve data completeness (see Evaluation of BLIS section of this report).

Special Populations: Medicaid Enrolled Children

Nationally, children enrolled in Medicaid tend to be more than twice as likely to have elevated blood lead levels as non-enrolled children. However, this disparity may differ between states and the CDC has recommended states develop screening plans consistent with their local risk patterns. A previous study of Minnesota blood lead surveillance data has indicated that the

---


disparity in EBLL prevalence between children enrolled in Medical Assistance (MA) or MinnesotaCare (MNCare), Minnesota’s Medicaid programs, and those not enrolled is similar to the national disparity, with an approximately 2-fold difference in prevalence.\(^9\) MA and MNCare’s Early and Periodic Screening, Diagnosis, and Treatment (EPSDT) program requires that well-child visits include blood lead testing at both 12 and 24 months. The MDH Blood Lead Screening Guidelines also recommend universal screening at 12 and 24 months for all MA or MNCare enrolled children.

The MDH LHHP and the Minnesota Department of Human Services (DHS) are currently revising data sharing agreements and matching protocols so that blood lead screening and blood lead levels can be more closely monitored in the Medicaid enrolled child population.

**Special Populations: Refugee Children**

Refugees are persons who are forced to leave their home country because of disasters, war, or persecution. Refugees come to Minnesota with a special immigration status and are a population at high risk for lead exposure. Refugees may have lead exposure in their country of origin, and further exposure once they are in the U.S. The Division of Infectious Disease Epidemiology, Prevention, and Control at MDH collects demographic data on refugee children aged less than 17 years entering the state who receive an initial health screening. Blood lead tests are routinely matched to refugee information (Figure 9). The rate of elevated blood lead levels for refugees is nearly ten times higher than the percentage of elevated blood lead levels among Minnesota children in general.

**Figure 9. Elevated Blood Lead Levels (EBLLs) among Refugee Children Who Received a Blood Lead Test**

![Figure 9](image)

**Case Management**

The LHHP provides technical assistance and coordinates with local public health agencies in the state of Minnesota to ensure case management services are available for children with blood lead levels of at least 5 μg/dL. These activities include:

- Assuring case management activities and follow-up testing for children and pregnant women are performed in accordance with MDH guidelines;
- Providing educational materials, in appropriate languages, to assist in communicating lead exposure prevention measures;

---

Communicating regularly with the Asbestos and Lead Compliance Unit to assess progress on open lead cases and facilitate communication between the Asbestos and Lead Compliance Unit and local lead case managers.

Follow-up Testing
MDH recommends follow-up tests for children with elevated blood lead screening tests. The period of time recommended for re-testing varies according to the initial blood level and the test type. Diagnostic venous testing is recommended for all capillary results of 5 μg/dL or greater. Of the 1,233 Minnesota children whose first elevated blood lead level was a capillary test in 2017, 746 (61%) received a follow-up venous test within 90 days (Figure 10). This is an improvement over 2011, the first year in which follow-up venous testing for capillary results in the 5-9.9 µg/dL range was recommended, when just 23% received follow-up tests within 90 days.

Timely follow-up testing is important both for identifying cases so that public health responses can be initiated and for detecting false-positive screening tests. Capillary tests, typically used for blood lead screening, are prone to false positive results. These can be due to contamination on a child’s finger or other contamination during the testing and analysis process. A false positive test is defined as an elevated capillary test with a follow-up venous test than is below 5 μg/dL within 90 days. In 2017, 447 of the 746 (60%) initial elevated capillary tests that received a venous follow-up test within 90 days were false positives. This proportion is dependent on the prevalence of elevated blood lead levels in the population and is expected to increase as the prevalence decreases.

Healthcare providers can help prevent false positive capillary tests by thoroughly cleaning a child’s finger prior to conducting a capillary test to remove any surface lead contamination. This should include thoroughly washing the child’s hand with soap and water before drawing blood, wearing gloves, and collecting only the blood that has “beaded” on the fingertip while avoiding the blood that has run down the finger.10

---

Environmental Risk Assessments

For children found to have an elevated blood lead level, identifying and removing the source of lead exposure is a priority. Not only does this prevent further exposure to the child who has already been exposed, it also prevents other children from being exposed to that lead hazard. Minnesota Statutes 144.9504, requires assessing agencies to ensure that children with venous blood lead levels 15 µg/dL or greater are provided risk assessment services to limit exposure to lead hazards. Assessing agencies are also authorized to conduct lead risk assessments and issue lead hazard reduction orders on a property for any child with a venous blood lead level 5 µg/dL or greater, as resources allow. Agencies currently performing assessments in Minnesota are MDH, the City of Minneapolis Health Department and St. Paul-Ramsey County Public Health. MDH conducts risk assessments for other assessing agencies through contractual agreements, servicing children outside of Minneapolis and Ramsey County.

In 2017, there were 61 children newly identified with venous confirmed EBLLs ≥ 15 µg/dL. 10 of these children lived in Minneapolis, 8 in St. Paul (Ramsey County), and 43 elsewhere in Minnesota. 30 of the 61 (49%) received a lead risk assessment within 10 working days of the blood lead test being reported to MDH and 56 (92%) received an assessment within 90 working days. The remaining five cases have not received a risk assessment at the time of this analysis. These cases have not received a risk assessment for reasons such as moving out of state, lack of a permanent residence, and inability of the risk assessing agency to locate the case. The median number of working days between the EBLL being reported to MDH and the risk assessment was 10 days (Interquartile range: 7, 14).

The 61 15+ µg/dL EBLL children tended to have common risk factors for lead exposure. Eighty-five percent lived in homes built prior to 1978 and 67% lived in homes built prior to 1950. Twenty-eight percent lived in Minneapolis or St. Paul. Six children had recently immigrated to U.S. and may have been exposed in their countries of origin and/or refugee camps.

Several of the ≥ 15 µg/dL EBLL cases had previously been identified as having an EBLL in the 5–14.9 µg/dL range. Eight of 61 (13%) had a venous-confirmed EBLL in the 5–14.9 µg/dL range more than one month prior to the ≥15 µg/dL test result. These cases represent opportunities for earlier intervention, where lead hazards likely could have been removed prior to the blood lead level rising over 15 µg/dL if there had been greater resources to conduct risk assessments at lower elevated blood lead levels.

During the lead risk assessments, lead hazards were identified for 95% of children (53 of 56 receiving an assessment). Many children had multiple hazards identified. Lead-based paint and/or lead contaminated indoor dust was identified as a possible source of lead exposure for 42 cases. Indoor dust is commonly contaminated by deteriorating lead-based paint in the house. Lead soil hazards, measured by laboratory analysis of soil samples, were identified at the residences of 17 cases. Other sources of lead were identified among 14 cases, including contaminated spices, contaminated cultural or religious items such as sindoor powder, swallowed lead-containing metallic objects, and take-home occupational lead contamination from an adult household member.

Not all types of potential hazards are tested during every risk assessment. For example, soil was not tested if there was no bare soil the child could have been exposed to. In addition, hazards tested and identified during risk assessments are not systematically reported to the MDH Lead
Program by local health departments, and some hazards tested and identified may be underreported. However, the figures presented in Table 2, interpreted as ‘ballpark’ estimates, show that lead based paint and/or dust hazards are tested during the majority of risk assessments (100% in this sample), and these hazards are present most of the time that they are tested (42 of 56, 75%). Soil hazards are tested less frequently, with results reported for 28 of 56 (50%) assessments, but are commonly identified when soil is tested (17 identified among 28 tested, 61%). Other hazards are tested less frequently, reported with 17 of 56 (30%) risk assessments.

**Table 2. Lead Hazards Assessed and Identified During Lead Risk Assessments for Children with EBLLs ≥15 µg/dL in 2017 (n=56)**

<table>
<thead>
<tr>
<th>Lead Hazard Type</th>
<th>Tested</th>
<th>Hazard Identified, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead-based paint and/or lead contaminated indoor dust</td>
<td>56</td>
<td>42 (75%)</td>
</tr>
<tr>
<td>Outdoor contaminated soil</td>
<td>28</td>
<td>17 (61%)</td>
</tr>
<tr>
<td>Contaminated drinking water</td>
<td>26</td>
<td>0 (0%)*</td>
</tr>
<tr>
<td>Other lead source</td>
<td>17</td>
<td>14 (82%)</td>
</tr>
<tr>
<td>Any Hazard Type</td>
<td>60</td>
<td>59 (98%)</td>
</tr>
<tr>
<td>Multiple Hazard Types†</td>
<td>43</td>
<td>19 (44%)</td>
</tr>
</tbody>
</table>

*Hazards in drinking water are shown in the table according to the EPA action level of 15 ppb. A detectable level of lead was found in four risk assessments; all were at concentrations less than 15 ppb.
†Includes paint/indoor dust (as a single type), soil, water, and other.

In 2017, MDH began testing routinely for lead-contaminated drinking water. Of the 26 residences tested for lead in water, 4 (15%) had a detectable level of lead in the water sample tested (Table 3). However, all tests completed were found to be below the EPA action level of 15 parts of lead per billion parts of water (ppb) for public water systems. A public water system has to take actions to reduce the amount of lead in the water if more than 10 percent of the water samples have lead levels over 15 ppb. This is an action level; there is no safe level of lead in water. There can still be lead in drinking water in Minnesota homes due to when homes were built. Homes built before 1940 may have lead service lines that connect them to public water. Plumbing systems built before 1986 may have lead parts.

Multiple types of lead hazards were often identified in homes. During 43 risk assessments where multiple hazard types (paint/dust, soil, water and/or other) were tested, more than one hazard type was identified in 19 cases (44%). This suggests that it may be common for children with elevated blood lead levels of 15+ µg/dL to be exposed to multiple sources of lead contamination. Testing all possible sources as part of a comprehensive risk assessment, even after one hazard or type of hazard is identified, may help in creating a lead-safe environment for the lead-exposed child and other children in that environment.
Table 3. Lead Levels in Drinking Water Tested During Risk Assessments in 2017 (n=26)

Adults

In adults, lead exposure can lead to increased risk for chronic diseases such as hypertension and kidney disease. The Adult Blood Lead Epidemiology and Surveillance (ABLES) program is an active surveillance program that follows up on EBLLs reported to BLIS among adults in Minnesota, and ascertains the source of lead exposure. This includes calling healthcare providers to determine the source of an adult’s lead exposure, including his or her employer information, job title, known non-occupational lead exposures, and pregnancy status. The National Institute for Occupational Safety and Health (NIOSH), CDC, and the State of Minnesota use a reference value of 5 µg/dL in adults, as well as children. MDH reports work-related blood lead levels of 25 µg/dL or greater to Minnesota Occupational Safety and Health Administration (MNOSHA) so MNOSHA can investigate the conditions that led to the EBLL. Adult lead testing is most common among people working in high-risk industries and pregnant women with either occupational or non-occupational risk factors for lead exposure.

The total number of BLL tests reported for adults in 2017 in Minnesota is presented in Table 4. There were 10,950 BLL tests performed in 2017 on 9,365 adults (aged ≥ 16 years). Of those 9,365 adults, 3,908 (42%) were men, 5,449 (58%) were women, and 8 had an unreported gender. Pregnancy status was unreported too often for reliable estimates. Of the adults tested, 10% had an EBLL of 5 µg/dL or greater, and of those people, 92% were under 25 µg/dL.

Although more women than men were tested during 2017, 92% of adults with an EBLL of at least 5 µg/dL were men. This was likely due to more men than women working in industries and occupations with high risk for lead exposure. Of the 983 adults with BLLs 5 µg/dL or greater, 778 (79%) were fully or partially due to occupational exposures, 48 (5%) were due to non-occupational exposures, and 157 (16%) were due to unknown exposures.
Table 4. Blood Lead Levels among Tested Adult (Aged 16+) Minnesota Residents

<table>
<thead>
<tr>
<th>2017 BLL Data</th>
<th>BLL &lt; 5 µg/dL</th>
<th>BLL 5-9 µg/dL</th>
<th>BLL 10-24 µg/dL</th>
<th>BLL ≥ 25 µg/dL</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of BLL Tests</td>
<td>8987</td>
<td>756</td>
<td>1076</td>
<td>131</td>
<td>10,950</td>
</tr>
<tr>
<td>Number of individuals tested</td>
<td>8382</td>
<td>454</td>
<td>450</td>
<td>79</td>
<td>9,365</td>
</tr>
<tr>
<td>Occupational Exposure</td>
<td>980</td>
<td>322</td>
<td>390</td>
<td>66</td>
<td>1758</td>
</tr>
<tr>
<td>Number of Men tested</td>
<td>852</td>
<td>298</td>
<td>382</td>
<td>64</td>
<td>1596</td>
</tr>
<tr>
<td>Number of Women tested</td>
<td>125</td>
<td>24</td>
<td>8</td>
<td>2</td>
<td>159</td>
</tr>
<tr>
<td>Non-Occupational Exposure</td>
<td>16</td>
<td>15</td>
<td>22</td>
<td>11</td>
<td>64</td>
</tr>
<tr>
<td>Number of Men tested</td>
<td>12</td>
<td>10</td>
<td>19</td>
<td>6</td>
<td>47</td>
</tr>
<tr>
<td>Number of Women tested</td>
<td>4</td>
<td>5</td>
<td>3</td>
<td>5</td>
<td>17</td>
</tr>
<tr>
<td>Unknown exposure source</td>
<td>7386</td>
<td>117</td>
<td>38</td>
<td>2</td>
<td>7543</td>
</tr>
<tr>
<td>Number of Men tested</td>
<td>2144</td>
<td>88</td>
<td>31</td>
<td>2</td>
<td>2265</td>
</tr>
<tr>
<td>Number of Women tested</td>
<td>5237</td>
<td>29</td>
<td>7</td>
<td>0</td>
<td>5273</td>
</tr>
</tbody>
</table>

EBLLs caused by occupational exposures were analyzed and are reported in Figure 11. Thirty-nine percent of the occupational exposures occurred in the secondary smelting industry, 26% occurred in the sporting and athletic goods manufacturing industry, and 6% occurred due to work in small arms ammunition manufacturing. Other occupational exposures included construction work, work in recreation industries, and contracted painting. Among people with EBLLs from non-occupational sources, shooting firearms as a hobby was the most common source, with casting bullets as the second most common source. The highest EBLL due to a non-occupational exposure was 45 µg/dL in an individual who shot firearms as a hobby.

**Figure 11. Work Related EBLLs Greater than or Equal to 5 µg/dL, by Industry**

- Secondary Smelting: 306, 39%
- Sporting and Athletic Goods Manufacturing: 204, 26%
- Small Arms Ammunition Manufacturing: 50, 6%
- Construction, Sand and Gravel Mining: 46, 6%
- Recreation Industries: 26, 3%
- Painting: 24, 3%
- Other: 99, 13%
- Unknown: 23, 3%
Evaluation of BLIS

MDH has been consistently improving the Blood Lead Information System (BLIS) through recent years. Improvements have been made in the completeness and timing of the data in the system.

Completeness

Extensive efforts are made by MDH staff to ensure the completeness of data in BLIS. This often involves contacting clinics and laboratories to obtain additional information when incomplete records are submitted to MDH and monitoring submissions from laboratories to detect and remediate any missed submissions. This has resulted in an improvement in the completeness of several variables that are necessary for both surveillance and case response functions of BLIS. The test type (venous or capillary) has improved from being undocumented on nearly 10% of records in 2000 to 0.3% in 2017. Test type is used for case confirmation and initiation of environmental risk assessment services. The completeness of address and phone number fields have also improved substantially. These variables help local public health agencies contact families of lead exposed children to provide public health services. Race and ethnicity would be useful for surveillance, to monitor disparities and identify high-risk populations, if the completeness were further improved. (Table 5).

Table 5. Completeness of Blood Lead Records Submitted to MDH by Year

<table>
<thead>
<tr>
<th>Year of Test</th>
<th>Test Type (Ven or Cap) Percent Missing</th>
<th>Race Ethnicity Percent Missing</th>
<th>Hispanic Ethnicity Percent Missing</th>
<th>Residential Address/ City/ZIP Code Percent Missing</th>
<th>Phone Number Percent Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>9%</td>
<td>43%</td>
<td>76%</td>
<td>11%</td>
<td>39%</td>
</tr>
<tr>
<td>2001</td>
<td>15%</td>
<td>46%</td>
<td>76%</td>
<td>9%</td>
<td>35%</td>
</tr>
<tr>
<td>2002</td>
<td>13%</td>
<td>46%</td>
<td>71%</td>
<td>6%</td>
<td>30%</td>
</tr>
<tr>
<td>2003</td>
<td>3%</td>
<td>45%</td>
<td>66%</td>
<td>6%</td>
<td>26%</td>
</tr>
<tr>
<td>2004</td>
<td>3%</td>
<td>43%</td>
<td>61%</td>
<td>7%</td>
<td>24%</td>
</tr>
<tr>
<td>2005</td>
<td>2%</td>
<td>40%</td>
<td>57%</td>
<td>9%</td>
<td>23%</td>
</tr>
<tr>
<td>2006</td>
<td>3%</td>
<td>37%</td>
<td>52%</td>
<td>9%</td>
<td>22%</td>
</tr>
<tr>
<td>2007</td>
<td>3%</td>
<td>37%</td>
<td>51%</td>
<td>7%</td>
<td>18%</td>
</tr>
<tr>
<td>2008</td>
<td>2%</td>
<td>37%</td>
<td>51%</td>
<td>6%</td>
<td>18%</td>
</tr>
<tr>
<td>2009</td>
<td>2%</td>
<td>36%</td>
<td>48%</td>
<td>5%</td>
<td>19%</td>
</tr>
<tr>
<td>2010</td>
<td>1%</td>
<td>37%</td>
<td>48%</td>
<td>4%</td>
<td>19%</td>
</tr>
<tr>
<td>2011</td>
<td>2%</td>
<td>36%</td>
<td>50%</td>
<td>2%</td>
<td>23%</td>
</tr>
<tr>
<td>2012</td>
<td>3%</td>
<td>34%</td>
<td>56%</td>
<td>2%</td>
<td>25%</td>
</tr>
<tr>
<td>2013</td>
<td>1%</td>
<td>35%</td>
<td>58%</td>
<td>2%</td>
<td>17%</td>
</tr>
<tr>
<td>2014</td>
<td>2%</td>
<td>35%</td>
<td>59%</td>
<td>2%</td>
<td>23%</td>
</tr>
<tr>
<td>2015</td>
<td>2%</td>
<td>32%</td>
<td>59%</td>
<td>1%</td>
<td>16%</td>
</tr>
<tr>
<td>2016</td>
<td>1%</td>
<td>34%</td>
<td>55%</td>
<td>1%</td>
<td>12%</td>
</tr>
<tr>
<td>2017</td>
<td>0%</td>
<td>34%</td>
<td>51%</td>
<td>1%</td>
<td>10%</td>
</tr>
</tbody>
</table>
Timing

The timing of the data in BLIS is measured by the time between a blood lead test, its submission to MDH, and its entry into BLIS.

The use of electronic reporting formats allows for greater efficiency in handling large numbers of records. The LHHP works with the Minnesota Electronic Disease Surveillance System (MEDSS) to incorporate electronic reporting of blood lead test results into routine data handling by MDH.

In 2017, there were 112,519 total blood lead tests reported to BLIS, 87% of which were received electronically via secure data connection, encrypted email, or secure web downloads. There were still 15,031 results received by paper reporting through mail or fax. Electronic reporting significantly improves timeliness and requires less staff time for entry of records into BLIS compared to paper reporting. Tests were received from 80 separate laboratories during 2017. Of these, 45 submitted primarily electronic records and 35 submitted primarily paper records.

The median total time from specimen collection to entry into BLIS was 8 days for electronic records during 2017, while the median total time to entry into BLIS for paper records was 22 days. This total time applies to blood lead test results below 5 µg/dL; results at or above 5 µg/dL that must be manually entered are separated and entered immediately upon receipt. (Figure 12)

Support of the state’s capacity to enter all records in a timely manner remains critical to addressing the needs of children who have been exposed to lead. In addition, the infrastructure for electronic laboratory reporting is critical to ensuring a timely public health surveillance system.

Figure 12. Median Timeframes for Electronic and Paper Blood Lead Test Results Reported to BLIS, 2017

[Diagram showing median timeframes for electronic and paper blood lead test results]
Other Resources Available from LHHP

The Lead Program maintains a web page through the MDH Web site that provides a number of lead education materials for providers, regulated parties, and the general public (www.health.state.mn.us/lead). This site contains numerous fact sheets, a list of “frequently asked questions”, all publications and reports (including guidelines for screening children and pregnant women, case management, and clinical treatment in children), and links to many external lead resources.

M-CLEAN

The Minnesota Collaborative Lead Education and Assessment Network (M-CLEAN) is a workgroup that discusses lead exposure prevention initiatives and legislative developments. Membership is open to all interested stakeholders. Organizations that typically participate in M-CLEAN include MDH, local public health agencies, other governmental agencies, community action agencies, non-profit organizations, and industry groups. More information on M-CLEAN meetings can be found at http://www.health.state.mn.us/divs/eh/lead/mclean/index.html.

Swab Team Services Grants

MDH has collaborated with community partners through Swab Team Services Grants since 2006. The grants are authorized under Minnesota Statutes 144.9512.

MDH’s Swab Team Services Grant provides nonprofit organizations with funding to:

▪ Increase the screening of children under six years and pregnant women to identify elevated blood lead levels (EBLL) in populations at high risk for lead exposure
▪ Plan, implement, and execute successful lead screening events in communities with high lead exposure
▪ Provide education and outreach services when an EBLL is identified
▪ Provide swab team services to protect populations from identified lead hazards in their residences

Organizations funded by the Swab Team Services Grants during 2017 were Sustainable Resources Center and CLEARCorps USA in Minneapolis and East Side Neighborhood Development Company in St. Paul.

Healthy Homes Information

In addition to lead exposure prevention responsibilities, the LHHP at MDH administers the Healthy Homes Program. This program distributes approximately $240,000 per year in grants to local agencies and organizations as authorized by Minnesota Statutes 144.9513, which defined healthy housing and established healthy housing grants. These grants address lead, asthma, radon, injuries, smoking, excessive moisture/mold, pests, carbon monoxide, fire hazards, and other home-related health hazards. Additional information on the Healthy Homes program and grants can be found at http://www.health.state.mn.us/topics/healthyhomes/ as well as in the
biennial LHHP Legislative Report, found at

**Further Lead Information**

More information about lead exposure prevention in Minnesota is available at the MDH Lead Program web site: http://www.health.state.mn.us/lead or by calling 651-201-4620.